Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Issued (2017 - 2023)

Aclaris Therapeutics (ACRS) has 7 years of Shares Issued data on record, last reported at $26.7 million in Q4 2023.

  • For Q4 2023, Shares Issued rose 136.74% year-over-year to $26.7 million; the TTM value through Dec 2024 reached -$45.9 million, down 271.79%, while the annual FY2024 figure was $32000.0, 99.88% down from the prior year.
  • Shares Issued reached $26.7 million in Q4 2023 per ACRS's latest filing, up from $15000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $72.6 million in Q3 2022 and bottomed at -$72.6 million in Q4 2022.
  • Average Shares Issued over 5 years is $2.6 million, with a median of $83000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: skyrocketed 1564.0% in 2021, then tumbled 99.98% in 2023.
  • A 5-year view of Shares Issued shows it stood at $122000.0 in 2019, then plummeted by 79.51% to $25000.0 in 2020, then skyrocketed by 4072.0% to $1.0 million in 2021, then plummeted by 7059.44% to -$72.6 million in 2022, then soared by 136.74% to $26.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $26.7 million in Q4 2023, $15000.0 in Q3 2023, and -$72.6 million in Q4 2022.